Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to
severe joint damage and disability. Significant progress has been made over the past 2 …

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly
developing, painful skin ulcers hallmarked by undermined borders and peripheral erythema …

Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

New treatment strategies have substantially changed the course of rheumatoid arthritis.
Many patients can achieve remission if the disease is recognised early and is treated …

Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2
that may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily targets
synovial joints, resulting in pain and functional limitations. It is the most common …

Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …

Objective We undertook this phase III study to evaluate baricitinib, an orally administered
JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to …